Maria Barceló‐Nicolau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Barceló‐Nicolau has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Albert Maimó-Barceló
Health Research Institute of the Balearic Islands (Institut d’Investigació Sanitària Illes Balears, IdISBa), Ctra. Valldemossa 79, E-07120 Palma, Balearic Islands, Spain
1 shared publication - Alice Chaplin
Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain
1 shared publication - Daniel Ramis-Cabrer
Health Research Institute of the Balearic Islands (IdISBa) Palma Spain
1 shared publication - Dora Romaguera
Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain
1 shared publication Elena Usamentiaga
Radiology Unit University Hospital Son Espases Palma Spain
1 shared publication- Gwendolyn Barceló-Coblijn
Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma, Spain
1 shared publication
Latest Publications
- 23 June 2025
- Published by Wiley in International Journal of Cancer
- Vol. 157 (9) , 1963-1975
Plasma fatty acids depletion: A metabolic signature related to colon cancer
Patients with colon cancer (CC) have decreased plasma fatty acid (FA) content, yet few studies have undertaken a systemic approach to understand this phenomenon. Patients with CC (n = 172) and healthy controls (n = 17) were recruited for this study at the University Hospital Son Espases (Spain). Clinical data was obtained from medical records. Plasma FA profile was analysed by gas chromatography–mass spectrometry. Body composition and hepatic steatosis were analysed using computerised tomography. Tumour tissue underwent transcriptomic analysis for consensus molecular subtype (CMS) stratification. Patients with CC (median age 73 years, 46.5% women) had significantly decreased total plasma FA content versus controls (median age 58 years, 41.2% women) (1510.0 nmol/mL vs. 4194.6 nmol/mL median values respectively, p < 0.001). This reduction (≥50%) was consistent across all species, independently of sex, age, body composition or cancer stage. An elevated unsaturated‐to‐saturated FA ratio was observed in CMS2 tumours (p = 0.01). Plasma inflammatory markers (C‐reactive protein and fibrinogen) were above normal range in patients in a stage‐dependent manner (p < 0.01). Hepatic enzymes fell within normal range, yet increased with tumour stage. This study indicates that plasma FA content reduction is an intrinsic metabolic alteration of CC already occurring in early stages. Further research will aid clinical significance.
- 23 June 2025
- Published by Wiley in International Journal of Cancer
- Vol. 157 (9) , 1963-1975
Plasma fatty acids depletion: A metabolic signature related to colon cancer
Patients with colon cancer (CC) have decreased plasma fatty acid (FA) content, yet few studies have undertaken a systemic approach to understand this phenomenon. Patients with CC (n = 172) and healthy controls (n = 17) were recruited for this study at the University Hospital Son Espases (Spain). Clinical data was obtained from medical records. Plasma FA profile was analysed by gas chromatography–mass spectrometry. Body composition and hepatic steatosis were analysed using computerised tomography. Tumour tissue underwent transcriptomic analysis for consensus molecular subtype (CMS) stratification. Patients with CC (median age 73 years, 46.5% women) had significantly decreased total plasma FA content versus controls (median age 58 years, 41.2% women) (1510.0 nmol/mL vs. 4194.6 nmol/mL median values respectively, p < 0.001). This reduction (≥50%) was consistent across all species, independently of sex, age, body composition or cancer stage. An elevated unsaturated‐to‐saturated FA ratio was observed in CMS2 tumours (p = 0.01). Plasma inflammatory markers (C‐reactive protein and fibrinogen) were above normal range in patients in a stage‐dependent manner (p < 0.01). Hepatic enzymes fell within normal range, yet increased with tumour stage. This study indicates that plasma FA content reduction is an intrinsic metabolic alteration of CC already occurring in early stages. Further research will aid clinical significance.